keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28712102/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-2-approaches-beyond-first-line-therapy-and-novel-biologic-agents-under-investigation
#1
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings. While not approved by the US Food and Drug Administration (FDA) in the first-line setting, the vascular endothelial growth factor (VEGF)-targeting agents ziv-aflibercept and ramucirumab are appropriate treatment options in the second-line setting, as is continuation of first-line bevacizumab. Tumor RAS mutational status is helpful to determine which patients may benefit from epidermal growth factor receptor (EGFR)-directed therapies, and other novel biomarkers (BRAF, HER2, and mismatch repair deficiency) allow us to select patients who may benefit from biologic therapies that are FDA-approved for other malignancies...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#2
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28708103/pharmacogenomics-of-targeted-agents-for-personalization-of-colorectal-cancer-treatment
#3
REVIEW
Alessia Bignucolo, Elena De Mattia, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli
The use of targeted agents in the treatment of metastatic colorectal cancer (CRC) has improved patient outcomes. Anti-epidermal growth factor receptor (anti-EGFR) agents (cetuximab and panitumumab) and antiangiogenic molecules (bevacizumab, regorafeninb, ramucirumab, and aflibercept) have been successfully integrated into clinical practice. Other drugs have been designed to target additional deregulated pathways in CRC, such as MAPK (mitogen-activated protein kinase)/PI3K-AKT (phosphatidylinositol-3-kinase-AKT serine/threonine kinase)/mTOR (mammalian target of rapamycin), HER-2 and 3 ( human epidermal growth factor receptor-2 and -3), and BRAF...
July 14, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28699051/-assessing-the-added-benefit-of-new-ophthalmic-drugs-which-additional-insights-can-be-extracted-from-the-early-benefit-assessment
#4
REVIEW
M Appelrath, G Glaeske
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added benefit, limited for 5 years) and another agent, idebenone, received an added benefit due to its orphan drug designation (proof of a not quantifiable added benefit, limited for 2 years)...
July 11, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28697703/retrospective-analysis-of-the-effect-of-aflibercept-loading-dose-on-the-retinal-vessel-diameters-in-patients-with-treatment-naive-neovascular-amd
#5
Mehmet Tetikoğlu, Muhammed Mustafa Kurt, Hacı Murat Sağdık, Serdar Aktaş, Medine Aslı Yıldırım, Fatih Özcura
BACKGROUND: To evaluate the effects of intravitreal aflibercept (IVA) on retinal vessel diameters in patients with neovascular age-related macular degeneration (AMD). DESIGN, SETTING, AND PARTICIPANTS: A retrospective study conducted at the Kutahya Dumlupinar University Faculty of Medicine included fifteen eyes of fifteen patients with treatment naive neovascular AMD. METHODS: All eyes received IVA injections once per month for 3 months; untreated contralateral eyes were used as controls...
July 11, 2017: Cutaneous and Ocular Toxicology
https://www.readbyqxmd.com/read/28697497/one-year-outcomes-following-intravitreal-aflibercept-for-polypoidal-choroidal-vasculopathy-in-japanese-patients-the-apollo-study
#6
Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Shigeo Yoshida, Koh-Hei Sonoda, Tatsuro Ishibashi
PURPOSE: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. METHODS: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. RESULTS: Fifty eyes with PCV were included in the study...
July 12, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28691937/macular-atrophy-and-macular-morphology-in-aflibercept-treated-neovascular-age-related-macular-degeneration
#7
Yoshimasa Kuroda, Kenji Yamashiro, Sotaro Ooto, Hiroshi Tamura, Akio Oishi, Hideo Nakanishi, Manabu Miyata, Masayuki Hata, Ayako Takahashi, Tomotaka Wakazono, Nagahisa Yoshimura, Akitaka Tsujikawa
PURPOSE: To investigate the incidence and predictors of macular atrophy during treatment with aflibercept for neovascular age-related macular degeneration in Japanese patients. METHODS: This study included patients with treatment-naive subfoveal neovascular age-related macular degeneration treated from December 2012 through January 2015. Patients were treated with bi-monthly aflibercept injections after 3 monthly loading injections for the first year. Diagnosis of retinal pigment epithelial atrophy was made based on color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence...
July 4, 2017: Retina
https://www.readbyqxmd.com/read/28682829/tumour-growth-increased-following-antiangiogenic-interruption-the-challenge-of-tumour-evaluation
#8
Sarra Oumrani, Marie-Anne Guillaumot, Bertrand Brieau, Ammar Oudjit, Chloé Léandri, Catherine Brezault, Stanislas Chaussade, Romain Coriat
Vascular endothelial growth factor inhibitors, led by bevacizumab, are considered the cornerstone of the therapy in metastatic colorectal carcinoma. We present the case of a patient with metastatic colorectal cancer who experienced rapid tumour growth with liver broad invasion after the withdrawal of an antivascular endothelial growth factor therapy, aflibercept. The rebound effect caused by the residual tumour inducing a regrowth after an initial controlled disease has already been stressed in mice and metastatic colorectal cancer patients following bevacizumab interruption...
July 5, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28671896/evaluation-of-macular-ischemia-in-eyes-with-central-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#9
Rima Ghashut, Yuki Muraoka, Sotaro Ooto, Yuto Iida, Yuko Miwa, Kiyoshi Suzuma, Tomoaki Murakami, Shin Kadomoto, Akitaka Tsujikawa, Nagahisa Yoshimura
PURPOSE: To quantitatively assess macular perfusion status using optical coherence tomography angiography in eyes with aflibercept-treated central retinal vein occlusion and resolved macular edema and to investigate the impact of macular morphology and perfusion status on visual function. METHODS: This prospective consecutive case series included 23 patients with central retinal vein occlusion. All patients received intravitreal aflibercept injections before analysis...
June 30, 2017: Retina
https://www.readbyqxmd.com/read/28669776/association-of-vascular-vs-avascular-subretinal-hyperreflective-material-with-aflibercept-response-in-age-related-macular-degeneration
#10
Yu Kawashima, Masayuki Hata, Akio Oishi, Sotaro Ooto, Kenji Yamashiro, Hiroshi Tamura, Manabu Miyata, Akihito Uji, Naoko Ueda-Arakawa, Akitaka Tsujikawa
PURPOSE: To investigate flow signal within subretinal hyperreflective material (SHRM) using optical coherence tomography angiography (OCTA) and its association with aflibercept treatment responses in treatment-naïve neovascular age-related macular degeneration (nAMD). DESIGN: Prospective consecutive interventional case series METHODS: Forty-four eyes of 44 patients with treatment-naive nAMD manifesting SHRM on OCT were studied. All patients underwent OCTA and received three monthly aflibercept injections...
June 29, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28669041/two-year-results-of-a-treat-and-extend-regimen-with-aflibercept-for-polypoidal-choroidal-vasculopathy
#11
Masahiro Morimoto, Hidetaka Matsumoto, Kensuke Mimura, Hideo Akiyama
PURPOSE: To evaluate the effects of aflibercept therapy using a treat-and-extend regimen on treatment-naïve polypoidal choroidal vasculopathy (PCV). METHODS: In a retrospective interventional case series of 58 eyes of 58 patients with PCV, we assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and number of injections for 2 years. Polypoidal lesions were also evaluated before treatment and after the loading phase by indocyanine green angiography...
July 1, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28665474/evaluation-of-pain-during-intravitreal-aflibercept-injections
#12
Sibel Doguizi, Mehmet A Sekeroglu, Merve Inanc, Mustafa A Anayol, Pelin Yilmazbas
PURPOSE: To evaluate the pain associated with intravitreal aflibercept injections. METHODS: The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0.05 mL aflibercept into the vitreous cavity using a 27-G needle. Additional variables including age, sex, indication for the injection, injection site by quadrant (superotemporal or inferotemporal), position during injection (sitting or supine), number of previous intravitreal injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic) were recorded and assessed with self-reported pain scores...
June 20, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28660523/posterior-reversible-encephalopathy-syndrome-during-treatment-with-aflibercept-5-fluorouracil-leucovorin-and-irinotecan-for-metastatic-colorectal-cancer
#13
Nikolaos Miaris, Joseph Sgouros, Margarita Gerolympou, Basilios Spyropoulos, Dionysios Drakopoulos, Stefania Gkoura, Helen Res, Epaminondas Samantas
No abstract text is available yet for this article.
June 29, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28660080/neovascular-age-related-macular-degeneration-in-the-very-old-%C3%A2-90-years-epidemiology-adherence-to-treatment-and-comparison-of-efficacy
#14
Yousif Subhi, Torben Lykke Sørensen
PURPOSE: To investigate neovascular age-related macular degeneration (AMD) in patients aged ≥90 years from several perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for discontinuation, and efficacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and Aflibercept. METHODS: In this retrospective chart review, we determined the prevalence and presenting characteristics by reviewing all data for patients referred to our department with treatment-naïve neovascular AMD...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28655794/diffusion-mri-phenotypes-predict-overall-survival-benefitfrom-anti-vegf-monotherapy-in-recurrent-glioblastoma-converging-evidence-from-phase-ii-trials
#15
Benjamin M Ellingson, Elizabeth Gerstner, Marion Smits, Raymond Y Huang, Rivka R Colen, Lauren E Abrey, Dana T Aftab, Gisela M Schwab, Colin Hessel, Robert J Harris, Ararat Chakhoyan, Renske Gahrmann, Whitney B Pope, Kevin Leu, Catalina Raymond, Davis C Woodworth, John F de Groot, Patrick Y Wen, Tracy Batchelor, Martin J van den Bent, Timothy F Cloughesy
Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozantinib, or aflibercept monotherapy at first or second recurrence. These findings were validated using a separate trial comparing bevacizumab with lomustine. <br /><br />Experimental Design: Patients with recurrent GBM and diffusion MRI from the monotherapy arms of 5 separate Phase II clinical trials were included: 1) cediranib (NCT00035656); 2) bevacizumab (BRAIN Trial, AVF3708g; NCT00345163); 3) cabozantinib (XL184-201; NCT00704288); 4) aflibercept (VEGF Trap; NCT00369590); and 5) bevacizumab or lomustine (BELOB; NTR1929)...
June 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28655307/short-term-efficacy-of-intravitreal-aflibercept-injections-for-retinal-angiomatous-proliferation
#16
Hung-Da Chou, Wei-Chi Wu, Nan-Kai Wang, Lan-Hsin Chuang, Kuan-Jen Chen, Chi-Chun Lai
BACKGROUND: To evaluate the short-term efficacy of intravitreal injections of aflibercept (IVA) to treat retinal angiomatous proliferation (RAP) and identify factors related to functional outcomes. METHODS: This retrospective case series consisted of 19 eyes in 19 patients with RAP. All 19 eyes received 3 monthly consecutive IVA. The primary outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) after the last IVA. RESULTS: Of the 19 treated eyes, 8 (42%) were pre-treated with 1 dose of bevacizumab one month prior to the initiation of treatment with aflibercept...
June 27, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28652928/ph-of-anti-vegf-agents-in-the-human-vitreous-low-impact-of-very-different-formulations
#17
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen
BACKGROUND: The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept. METHODS: Fresh human vitreous samples were obtained during core vitrectomy (23-gauge) from patients with epiretinal gliosis. Aliquots of bevacizumab, ranibizumab, aflibercept or ziv-aflibercept (2 µl) were added consecutively to 200 µl of vitreous samples or 0.9% NaCl saline. The pH was measured using a pH-sensitive microelectrode...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28651842/sulodexide-prevents-activation-of-the-pla2-cox-2-vegf-inflammatory-pathway-in-human-retinal-endothelial-cells-by-blocking-the-effect-of-age-rage
#18
Giovanni Giurdanella, Francesca Lazzara, Nunzia Caporarello, Gabriella Lupo, Carmelina Daniela Anfuso, Chiara M Eandi, Gian Marco Leggio, Filippo Drago, Claudio Bucolo, Salvatore Salomone
Diabetic retinopathy is characterized by the breakdown of endothelial blood-retinal barrier. We tested the hypothesis that sulodexide (SDX), a highly purified glycosaminoglycan composed of 80% iduronylglycosaminoglycan sulfate and 20% dermatan sulfate, protects human retinal endothelial cells (HREC) from high glucose (HG)-induced damage, through the suppression of inflammatory ERK/cPLA2/COX-2/PGE2 pathway, by blocking the effect of advanced glycation end-products (AGEs). HREC were treated with HG (25mM) or AGEs (glycated-BSA, 2mg/ml) for 48h, with or without SDX (60μg/ml) or aflibercept (AFL, 40μg/ml), a VEGF-trap...
June 23, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28651811/bilateral-juxtapapillary-retinal-capillary-haemangioma-usefulness-of-aflibercept-in-the-management-of-its-complications
#19
R Campos Polo, C Rubio Sánchez, D M García Guisado, M J Díaz Luque
CASE REPORT: A 45 year-old man with a history of adrenal phaeochromocytoma presented with a subretinal juxtapapillary haemorrhage on his left eye and a small asymptomatic vascular tumour in the contralateral eye. With the mentioned findings, the patient was diagnosed with bilateral retinal capillary haemangioma in the context of a von Hippel Lindau disease. Intravitreal aflibercept was prescribed, with a good outcome of the disease. DISCUSSION: Many treatments have been proposed for the management of juxtapapillary retinal capillary haemangioma with variable results...
June 23, 2017: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28649871/the-potential-role-of-nintedanib-in-treating-colorectal-cancer
#20
Antonio Rossi, Tiziana Pia Latiano, Paola Parente, Cinzia Chiarazzo, Filomena Limosani, Gabriele Di Maggio, Evaristo Maiello
Angiogenesis leads to the growth, progression, and metastases of a variety of solid tumors, including metastatic colorectal cancer (mCRC), involving particularly the family of vascular endothelial growth factors (VEGF) and their receptors (VEGFR). Several anti-angiogenic inhibitors are already registered for mCRC therapy: bevacizumab, aflibercept, ramucirumab, regorafenib. Nintedanib is a new triple angiokinase oral inhibitor that potently blocks the proangiogenic pathways mediated by VEGFR, platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR)...
August 2017: Expert Opinion on Pharmacotherapy
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"